Abstract
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with a poor prognosis where incidence mirrors mortality. Gemcitabine and gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor) are the only FDA approved therapies for unresectable or metastatic PDA and are at best palliative. Hence, considerable efforts have been initiated to identify novel targets for monoclonal antibody (Mab) therapies that may safely and effectively be combined with gemcitabine. Mabs to cell surface receptors and/or their ligands have shown efficacy in pre-clinical and clinical studies in both solid and hematological malignancies and can safely be given with chemotherapy. A number of clinical trials have evaluated the safety and efficacy of Mabs targeting the tumor and/or tumor micro-environment and in combination with chemotherapy for PDA with very little success. Here we review the rationale for Mab therapies, targeted clinical trials, rational basis for target selection, pre-clinical models and promising novel cell surface targets and/or growth factor ligands that are amenable to ongoing and future Mab therapies that hold promise and hope for patients and their families with this devastating disease.
Keywords: Monoclonal antibodies, targeted therapies, cell surface receptors, growth factors
Current Drug Discovery Technologies
Title: Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Volume: 3 Issue: 4
Author(s): Kevin Engelhardt, Christopher Riley, Laurence Cooke and Daruka Mahadevan
Affiliation:
Keywords: Monoclonal antibodies, targeted therapies, cell surface receptors, growth factors
Abstract: Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with a poor prognosis where incidence mirrors mortality. Gemcitabine and gemcitabine plus erlotinib (epidermal growth factor receptor tyrosine kinase inhibitor) are the only FDA approved therapies for unresectable or metastatic PDA and are at best palliative. Hence, considerable efforts have been initiated to identify novel targets for monoclonal antibody (Mab) therapies that may safely and effectively be combined with gemcitabine. Mabs to cell surface receptors and/or their ligands have shown efficacy in pre-clinical and clinical studies in both solid and hematological malignancies and can safely be given with chemotherapy. A number of clinical trials have evaluated the safety and efficacy of Mabs targeting the tumor and/or tumor micro-environment and in combination with chemotherapy for PDA with very little success. Here we review the rationale for Mab therapies, targeted clinical trials, rational basis for target selection, pre-clinical models and promising novel cell surface targets and/or growth factor ligands that are amenable to ongoing and future Mab therapies that hold promise and hope for patients and their families with this devastating disease.
Export Options
About this article
Cite this article as:
Engelhardt Kevin, Riley Christopher, Cooke Laurence and Mahadevan Daruka, Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma, Current Drug Discovery Technologies 2006; 3 (4) . https://dx.doi.org/10.2174/157016306780368108
DOI https://dx.doi.org/10.2174/157016306780368108 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
α-Methylene-γ-lactones as a Novel Class of Anti-leukemic Agents
Anti-Cancer Agents in Medicinal Chemistry In-Silico Analysis of rSNPs in miRNA:mRNA Duplex Involved in Insulin Signaling Genes Shows a Possible Pathogenesis of Insulin Resistance
MicroRNA An Integrated Drug Development Approach Applying Topological Descriptors
Current Computer-Aided Drug Design Stem Cell Transplant and Idiotypic Vaccination for B-Cell Malignancies
Current Topics in Medicinal Chemistry Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue Presenting as Multiple Pulmonary Lesions: Case Report and Review of the Literature
Current Respiratory Medicine Reviews Single Nucleotide Polymorphisms as the Efficient Prognostic Markers in Breast Cancer
Current Cancer Drug Targets Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Antiangiogenic Therapy and Ovarian Cancer
Current Women`s Health Reviews Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry Proteasomes as Drug Targets
Current Drug Targets Alkylboronate Synthesis Based on Transition Metal-Catalyzed Hydroboration.
Current Organic Synthesis Synthesis, Characterization and Theoretical Studies of Novel Phosphonates as uPA Inhibitors
Current Organic Chemistry Rheumatologic Manifestations of Hematologic Neoplasms
Current Rheumatology Reviews Interferon alpha for Treatment of Chronic Myeloid Leukemia
Current Drug Targets Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism Cellular Senescence and Anti-Cancer Therapy
Current Drug Targets Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Turnover: An Evidence-Based Review
Reviews on Recent Clinical Trials Targeted Strategies in the Treatment of Primary Gastric Lymphomas: From Rituximab to Recent Insights into Potential New Drugs
Current Medicinal Chemistry Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology